Does insulin therapy for type 1 diabetes mellitus protect against Alzheimer's disease?

Pharmacotherapy

Volumn 34, Issue 12, 2014, Pages 1317-1323

  Rdzak, Grzegorz M ^a   Abdelghany, Osama ^a  

^a YALE NEW HAVEN HOSPITAL   (United States)

Author keywords

Alzheimer; insulin; memory; prevention; type 1 diabetes mellitus

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; GLUCOSE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; GLYCOGEN SYNTHASE KINASE 3; INSULIN; INSULIN RECEPTOR; SOMATOMEDIN; TAU PROTEIN; TUBULIN;

ALZHEIMER DISEASE; AMYLOID PLAQUE; DECLARATIVE MEMORY; DOWN REGULATION; DRUG EFFICACY; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; INSULIN BINDING; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LIGAND BINDING; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN POLYMERIZATION; REVIEW; SELECTIVE ATTENTION; AGED; DIABETES MELLITUS, TYPE 1; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; DIABETES MELLITUS, TYPE 1; HUMANS; INSULIN;

EID: 84919845700     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1494     Document Type: Review

References (50)

1. Thies W, Bleiler L,. 2013 Alzheimer's disease facts and figures. Alzheimers Dement 2013; 9: 208-45.
2. Hebert LE, Weuve J, Scherr PA, Evans DA,. Alzheimer's disease in the United States (2010-2050) estimated using the 2010 Census. Neurology. Available from www.neurology.org/content/early/2013/02/03/WNL.0b013e31828726f5.abstract. (Epub ahead of print, February 6, 2013). Accessed September 2013.
3. McCrimmon R, Shervin R,. Hypoglycemia in type 1 diabetes. Diabetes 2010; 59: 2333-9.
4. Miller RG, Secrest AM, Sharma RK, Songer TJ, Orchard TJ,. Improvements in the life expectancy of type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications study cohort. Diabetes 2012; 61: 2987-92.
5. Banks WA, Jaspan JB, Huang W, Kastin AJ,. Transport of insulin across the blood-brain barrier: saturability at euglycemic doses of insulin. Peptides 1997; 18: 1423-9.
6. Schwartz MW, Sipols A, Kahn SE, et al. Kinetics and specificity of insulin uptake from plasma into cerebrospinal fluid. Am J Physiol 1990; 259: E378-83.
7. Pardridge WM, Eisenberg J, Yang J,. Human blood-brain barrier insulin receptor. J Neurochem 1985; 44: 1771-8.
8. Ngarmukos C, Baur EL, Kumagai AK,. Co-localisation of GLUT1 and GLUT4 in the blood-brain barrier of the rat ventromedial hypothalamus. Brain Res 2001; 900: 1-8.
9. Hopkins DF, Williams G,. Insulin receptors are widely distributed in human brain and bind human and porcine insulin with equal affinity. Diabet Med 1997; 14: 1044-50.
10. Bingham EM, Hopkins D, Smith D, et al. The role of insulin in human brain glucose metabolism: an 18fluoro-deoxyglucose positron emission tomography study. Diabetes 2002; 51: 3384-90.
11. Clarke DW, Boyd FT Jr, Kappy MS, Raizada MK,. Insulin binds to specific receptors and stimulates 2-deoxy-D-glucose uptake in cultured glial cells from rat brain. J Biol Chem 1984; 259: 11672-5.
12. Page KA, Williamson A, Yu N, et al. Medium-chain fatty acids improve cognitive function in intensively treated type 1 diabetic patients and support in vitro synaptic transmission during acute hypoglycemia. Diabetes 2009; 58: 1237-44.
13. Austin EJ, Deary IJ,. Effects of repeated hypoglycemia on cognitive function: a psychometrically validated reanalysis of the Diabetes Control and Complications Trial data. Diabetes Care 1999; 22: 1273-7.
14. Brands A, Kessels R, Hoogma R, et al. Cognitive performance, psychological well-being, and brain magnetic resonance imaging in older patients with type 1 diabetes. Diabetes 2006; 55: 1800-6.
15. Lobing B, Optenhoster-Porstt C, Wolft O,. Hippocampal volume and cognitive performance in long-standing Type 1 diabetic patients without macrovascualr complications. Diabet Med 2006; 23: 32-9.
16. Crane PK, Walker R, Larson EB,. Glucose levels and risk of dementia. N Engl J Med 2013; 369: 540-8.
17. Ohara T, Doi Y, Ninomiya T, et al. Glucose tolerance status and risk of dementia in the community: the Hisayama study. Neurology 2011; 77: 1126-34.
18. Kim B, Backus C, Oh S, Feldman EL,. Hyperglycemia-induced tau cleavage in vitro and in vivo: a possible link between diabetes and Alzheimer's disease. J Alzheimers Dis 2013; 34: 727-39.
19. Steen E, Terry BM, Rivera EJ, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis 2005; 7: 63-80.
20. Talbot K, Wang HY, Kazi H, et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012; 122: 1316-38.
21. Kalaria RN, Harik SI,. Reduced glucose transporter at the blood-brain barrier and in cerebral cortex in Alzheimer disease. J Neurochem 1989; 53: 1083-8.
22. Simpson IA, Chundu KR, Davies-Hill T, Honer WG, Davies P,. Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease. Ann Neurol 1994; 35: 546-51.
23. Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D Jr,. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease. Neurology 1998; 50: 164-8.
24. Frolich L, Blum-Degen D, Hoyers S, Riederer P,. Regional distribution of insulin, insulin receptors and IGF-I receptors in post-mortem brain cortex in aging and in dementia of Alzheimer type. Neurobiol Aging 1996; 17: s184.
25. Henneberg N, Hoyer S,. Desensitization of the neuronal insulin receptor: a new approach in the etiopathogenesis of late-onset sporadic dementia of the Alzheimer type (SDAT)? Arch Gerontol Geriatr 1995; 21: 63-74.
26. Plastino M, Fava A, Pirritano D, et al. Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and diabetes mellitus type-2. J Neurol Sci 2010; 228: 112-6.
27. Craft S, Asthana S, Newcomer JW, et al. Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch Gen Psychiatry 1999; 56: 1135-40.
28. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT,. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 2011; 1: a006189.
29. Gouras GK, Tsai J, Naslund J, et al. Intraneuronal Abeta42 accumulation in human brain. Am J Pathol 2000; 156: 15-20.
30. Lambert MP, Barlow AK, Chromy BA, et al. Diffusible, nonfibrillar ligands derived from A beta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998; 95: 6448-53.
31. Zheng H, Koo EH,. Biology and pathophysiology of the amyloid precursor protein. Mol Neurodegener 2011; 6: 27.
32. Gasparini L, Gouras GK, Wang R, et al. Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci 2001; 21: 2561-70.
33. De Felice FG, Vieira MN, Bomfim TR, et al. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic biding of Abeta oligomers. Proc Natl Acad Sci USA 2009; 106: 1971-6.
34. Hong M, Lee VM,. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem 1997; 272: 19547-53.
35. Cvetkovic-Doxic D, Skender-Gazibora M, Dozic S,. Neuropathological hallmarks of Alzheimer's disease. Arch Oncol 2001; 9: 195-9.
36. Armstrong RA,. Is the clustering of neurofibrillary tangles in Alzheimer's patients related to the cells of origin of specific cortico-cortical projections? Neurosci Lett 1993; 160: 57-60.
37. Hasselbalch SG, Knudsen GM, Jakobsen J, Hageman LP, Holm S, Paulson OB,. Brain metabolism during short-term starvation in humans. J Cereb Blood Flow Metab 1994; 14: 125-31.
38. Veneman T, Mitrakou A, Mokan M, Cryer P, Gerich J,. Effect of hyperketonemia and hyperlacticacidemia on symptoms, cognitive dysfunction, and counterregulatory hormone responses during hypoglycemia in normal humans. Diabetes 1994; 43: 1311-7.
39. Amiel SA, Archibald HR, Chusney G, Williams AJ, Gale EA,. Ketone infusion lowers hormonal responses to hypoglycaemia: evidence for acute cerebral utilization of a non-glucose fuel. Clin Sci (Lond) 1991; 81: 189-94.
40. Maran A, Cranston I, Lomas J, Macdonald I, Amiel SA,. Protection by lactate of cerebral function during hypoglycaemia. Lancet 1994; 343: 16-20.
41. Magistretti PJ, Allaman I,. Brain energy metabolism. In:, Pfaff, DW, ed. Neuroscience in the 21st Century. New York: Springer, 2013: 1591-620.
42. Traul KA, Driedger A, Ingle DL, Nakhasi D,. Review of the toxicologic properties of medium-chain triglycerides. Food Chem Toxicol 2000; 38: 79-98.
43. Pan JW, Rothman TL, Behar KL, Stein DT, Hetherington HP,. Human brain beta-hydroxybutyrate and lactate increase in fasting-induced ketosis. J Cereb Blood Flow Metab 2000; 20: 1502-7.
44. De Feo P, Perriello G, De Cosmo S, et al. Comparison of glucose counterregulation during short-term and prolonged hypoglycemia in normal humans. Diabetes 1986; 35: 563-9.
45. Nemoto EM, Hoff JT, Severinghaus JW,. Lactate uptake and metabolism by brain during hyperlactatemia and hypoglycemia. Stroke 1974; 5: 48-53.
46. Alzheimer's Disease Cooperative Study. SNIFF: Study of Nasal Insulin to Fight Forgetfulness. Available from http://www.adcs.org/Studies/SNIFF.aspx. Accessed July 12, 2013.
47. Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment. Arch Neurol 2012; 69: 29-38.
48. Benedict C, Hallschmid M, Hatke A, et al. Intranasal insulin improves memory in humans. Psychoneuroendocrinology 2004; 29: 1326-34.
49. Watson GS, Craft S,. Modulation of memory by insulin and glucose: neurophsychological observations in Alzheimer's disease. Eur J Pharmacol 2004; 490: 97-113.
50. Reger MA, Watson GS, Green PS, et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 2008; 70: 440-8.